louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT07011381: Parental Perception of Oral Health-Related Quality of Life in Sudanese Refugee vs. Egyptian Children
Official title: Parental Perception of Oral Health-Related Quality of Life Among Sudanese Refugee Children Compered to Egyptian Children
Study type: OBSERVATIONAL
Overall status: ENROLLING_BY_INVITATION
Conditions: Dental Caries
Gingivitis
Oral Health
Refugee Health
Keywords: dental caries
gingivitis
oral health
refugee health
Lead sponsor: Kafrelsheikh University
Sponsor class: OTHER
First posted: 2025-06-08
Enrollment: 200
Sex: ALL
Minimum age (years): 6
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Sudanese refugee and Egyptian children aged 6-12 years attending selected schools and community centers in Cairo, Egypt.

Brief summary: This cross-sectional analytical study aims to assess and compare parental perceptions of oral health-related quality of life (OHRQoL) among Sudanese refugee children and Egyptian children aged 6-12 years living in Egypt. The study will include 192 child-parent pairs (96 Sudanese refugees and 96 Egyptians). Data will be collected via a validated Arabic questionnaire adapted from the Child Oral Health Impact Profile (COHIP) and clinical oral health examinations using DMFT/dmft indices, Gingival Index, and Plaque Index. The study seeks to identify disparities in oral health, parental awareness, and access to dental care services, thereby informing future community-based interventions and public health policies targeting vulnerable populations such as refugee children.


Eligibility criteria: Inclusion Criteria:

Children aged 6-12 years

Either Sudanese refugee or Egyptian national

Resident in Cairo for at least 1 year

Informed consent obtained from parent or legal guardian

Exclusion Criteria:

Systemic health conditions affecting oral health

Ongoing orthodontic treatment

Children with special health care needs or developmental disabilities

Primary outcomes:
measure: Mean Total Score on the Child Oral Health Impact Profile (COHIP) Questionnaire
timeFrame: Baseline (single clinical visit at enrollment)
Secondary outcomes:
measure: Clinical Oral Health Status
timeFrame: Baseline (Day 1, clinical oral examination)
Other outcomes:
Locations:
city: Kafr ash Shaykh
country: Egypt
facility: Kafrelsheikh University, Faculty of Oral and Dental Medicine
state: kafr ash Shaikh/ elhamrawy
Study officials:
References:
Clinical trial NCT01335581: Study of Laser Treatment of Melasma
Official title: A Study of the RevLite Q-Switched Nd:YAG Laser System With Smart Infinite (SI) Handpiece for the Treatment of Refractory Mixed Type Melasma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Refractory Mixed Type Melasma
Lead sponsor: Cynosure, Inc.
Sponsor class: INDUSTRY
First posted: 2011-04-14
Enrollment: 18
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the RevLite laser in the treatment of refractory mixed type melasma.


Eligibility criteria: Inclusion Criteria:

* Fitzpatrick Skin Type III-VI
* mixed (epidermal and dermal) melasma diagnosed by Wood's Lamp exam
* age 18 or older
* melasma persisting for greater than 6 months that has failed to respond to conventional treatment with hydroquinone or other topical lightening agents
* written and verbal informed consent
* willing and able to comply with study instructions and return to the clinic for required visits

Exclusion Criteria:

* Pregnancy, breastfeeding, taking birth control pills or plans to become pregnant during the study
* history of cutaneous photosensitization, porphyria, and hypersensitivity to porphyrins or photodermatosis
* any skin pathology or condition that could interfere with the evaluation or requires the use of interfering topical or systemic therapy
* uncorrected coagulation defect or is currently using anti-coagulation medication (including but not limited to heavy aspirin therapy)
* any condition which, in the investigator's opinion, would make it unsafe for the subject to participate in this research study
* currently enrolled in an investigational drug or device trial, or has received an investigational drug or has been treated with an investigational device within 30 days prior to entering this study
* inability to communicate or cooperate with the investigator due to language problems, poor mental development, or impaired cerebral function
* unreliability for the study (this includes subjects who engage in excessive alcohol intake or drug abuse, or subjects who are unable to return for scheduled follow-up visits)
* use of photosensitizing drugs within a timeframe where photosensitization from these drugs may still be present
* need to be exposed to artificial tanning devices or excessive sunlight during the trial
* Diabetes Type I or II
* sensitivity to hydroquinone or Retin-A
* evidence of a compromised immune system or hepatitis
* use of bleaching creams or retinoids within the last 30 days

Primary outcomes:
measure: Melasma Area Severity Assessment (MASI) Score Change From Baseline to Follow Up
timeFrame: 3 Months
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: New York Laser and Skin Care
state: New York
Study officials:
affiliation: New York Laser and Skin Care
name: Arielle Kauvar, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01550081: Target Heart Rate and Aerobic Interval Training
Official title: Exercise Intensity and Target Heart Rate During Aerobic Interval Training in Cardiac Rehabilitation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Coronary Artery Disease
Keywords: exercise intensity
aerobic interval training
cardiac rehabilitation
group exercise
Lead sponsor: Norwegian University of Science and Technology
Sponsor class: OTHER
First posted: 2012-03-09
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: DIAGNOSTIC

Brief summary: Aerobic interval training is shown to be superior in increasing oxygen uptake in both healthy and patients with coronary artery disease (CAD), compared to moderate continuous training. However, in cardiac rehabilitation exercise groups, exercise intensity is usually controlled with perceived exertion (Borg scale). The investigators will investigate degree of agreement between target heart rate and perceived exertion during interval training in cardiac rehabilitation.


Eligibility criteria: Inclusion Criteria:

* referred to cardiac rehabilitation
* able to perform exercise treadmill test

Exclusion Criteria:

* unstable angina
* severe arrhythmias
* heart failure

Primary outcomes:
measure: degree of agreement between target heart rate (THR) and perceived exertion
timeFrame: up to 1 hour
Secondary outcomes:
Other outcomes:
Locations:
city: Trondheim
country: Norway
facility: Department of circulation and medical imaging, NTNU
state: Sør-Trøndelag
Study officials:
affiliation: Norwegian University of Science and Technology
name: Inger-Lise Aamot, MSc
role: PRINCIPAL_INVESTIGATOR
References:
citation: Aamot IL, Forbord SH, Karlsen T, Stoylen A. Does rating of perceived exertion result in target exercise intensity during interval training in cardiac rehabilitation? A study of the Borg scale versus a heart rate monitor. J Sci Med Sport. 2014 Sep;17(5):541-5. doi: 10.1016/j.jsams.2013.07.019. Epub 2013 Aug 8.
Clinical trial NCT03614481: Clinical and Genetic Analyzes of Age-related Macular Degeneration
Official title: Clinical and Genetic Analyzes of Age-related Macular Degeneration
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Macular Degeneration
Lead sponsor: Centre Hospitalier Intercommunal Creteil
Sponsor class: OTHER
First posted: 2018-08-03
Enrollment: 6000
Sex: ALL
Minimum age (years): 55
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Diagnosis of exudative or atrophic AMD

Brief summary: The purpose of this collection is to search for susceptibility genes for age-related macular degeneration (AMD) alone or in combination with environmental factors and to look for genes that modulate the AMD phenotype (particularly the response to treatment).


Eligibility criteria: Inclusion Criteria:

* Age\> 55 years
* Diagnosis of exudative or atrophic AMD in at least one eye
* Patient informed of the objectives of the study and having freely signed the informed consent letter
* Patient affiliated to a social security scheme

Exclusion Criteria:

* Other retinal or choroidal lesion in the studied eye
* History of severe systemic disease that could potentially hinder patient adherence to the study protocol: mental disorder, cancer, recent stroke or heart failure less than 3 months old.
* Known allergy to fluorescein, indocyanine green, iodine or ranibizumab

Primary outcomes:
measure: Genotypic factors
timeFrame: 6 months
Secondary outcomes:
measure: Predictive markers
timeFrame: 6 months
measure: Vascular Endothelial Growth Factor
timeFrame: 6 months
measure: Environmental factors
timeFrame: 6 months
measure: Predictive treatment response score
timeFrame: 6 months
measure: Circulating biological factors
timeFrame: 6 months
Other outcomes:
Locations:
city: Bordeaux
country: France
facility: Hôpital Pellegrin
city: Créteil
country: France
facility: CHI Créteil
city: Dijon
country: France
facility: Hôpital général de Dijon
city: Paris
country: France
facility: Hôpital des Quinze-Vingts
city: Paris
country: France
facility: Centre ophtalmologique d'imagerie et de laser
Study officials:
References:
Clinical trial NCT01344681: Micafungin Versus Intravenous Itraconazole as Empirical Antifungal Therapy for Febrile Neutropenic Patients With Hematological Diseases
Official title: A Randomized Phase II, Multi-center, Non-inferiority Clinical Trial for Efficacy and Safety of Micafungin Versus Intravenous Itraconazole as Empirical Antifungal Therapy for Febrile Neutropenic Patients With Hematological Diseases
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Febrile Neutropenia
Hematological Diseases
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2011-04-29
Enrollment: 153
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study of chemotherapy occurred during the neutropenic fever in patients with antibiotic refractory fever. The investigators evaluate efficacy and safety of micafungin sodium (mycamine ® Injection) 100mg dose compare to itraconazole (Sporanox ® Injection) 200mg as a control and this study is prospective, randomized, non-inferiority trials.

Therefore, this study was planned for review of the safety and efficacy in korean patients.


Eligibility criteria: Inclusion Criteria:

* The male and female patients over 18 years
* To participate in clinical trials and voluntary written consent requirement to comply with a patient
* Chemotherapy with a variety of hematologic malignancies or patients undergoing stem cell transplantation
* Fever (temperature ≥ 38.4 ℃) showing Neutropenia (absolute neutrophil count \<500/mm3) patients
* Combined antibiotic therapy 72 hours after the expiration of term lasts three patients

Exclusion Criteria:

* Of clinical trials of breast-feeding or pregnant women of childbearing age with intent to
* Adapted species (candida genus, aspergillus genus) Colitis caused by fungi other than the patients with fungal infection
* HIV-positive patient serum
* This test within 30 days of assignment to the other patients participating in clinical trials
* Within 72 hours of registration before the patients treated with systemic antifungal agents

Primary outcomes:
measure: Responses to therapy
timeFrame: 7 days after stopping study medication
Secondary outcomes:
Other outcomes:
Locations:
city: Busan
country: Korea, Republic of
facility: Dong-A Medical Center
city: Seoul
country: Korea, Republic of
facility: Severance Hospital
city: Seoul
country: Korea, Republic of
facility: Korea University Guro Hospital
city: Seoul
country: Korea, Republic of
facility: ASAN Medical Center
city: Seoul
country: Korea, Republic of
facility: Ewha Womans University Mokdong Hospital
city: Seoul
country: Korea, Republic of
facility: Samsung Medical Center
city: Suwon
country: Korea, Republic of
facility: Ajou University Medical Center
Study officials:
References:
Clinical trial NCT02400281: Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients
Official title: Phase I-II Study of Crenolanib Combined With Standard Salvage Chemotherapy, and Crenolanib Combined With 5-Azacitidine in Acute Myeloid Leukemia Patients With FLT3 Activating Mutations
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Acute Myeloid Leukemia
Lead sponsor: Arog Pharmaceuticals, Inc.
Sponsor class: INDUSTRY
First posted: 2015-03-27
Enrollment: 28
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is an open label, two-arm, Phase I-II trial, non-randomized. Arm 1: crenolanib with standard chemotherapy (Idarubicin/Cytarabine, MEC;Mitoxantrone/Etoposide/Cytarabine, FLAG-Ida: Fludarabine/Cytarabine/G-CSF/Idarubicin) Arm 2: crenolanib with 5-azacitidine

Detailed description: For each arm:

The phase I with dose-limiting toxicity (DLT) determination will use 3+3 design.

Phase II total of 52 patients (26 per arm) will be treated at established phase I dose.

Enrollment to be simultaneous to each arm.

Eligibility criteria: Inclusion Criteria:

1. Confirmed diagnosis of refractory/relapsed AML or high-risk MDS

   * Arm 1: Subjects must have received at least one prior therapy and a maximum of three prior therapies
   * Arm 2: Subjects must have received at least one prior therapy and a maximum of three prior therapies. No prior treatment with 5-Azacitidine is allowed in this arm.
2. FLT3 mutation positive (ITD, TKD or other)
3. ECOG PS 0-2
4. Adequate liver and renal function
5. Negative pregnancy test
6. Extramedullary leukemia allowed except CNS disease

Exclusion Criteria:

* Arm 1 and 2 Exclusion:

  1. \<5% blasts in marrow or blood at time of screening
  2. Active HIV, hepatitis B or C
  3. CNS leukemia
  4. Clinically significant GVHD or organ dysfunction where chemotherapy specified by protocol cannot be given
  5. Patient with AML-M3 (APL)
  6. Pre-existing liver diseases (i.e. cirrhosis, chronic hepatitis B or C, nonalcoholic steatohepatitis, sclerosing cholangitis)

Primary outcomes:
measure: Response Rate of Crenolanib Besylate Combination Therapy
timeFrame: Baseline up to first documented response, persistent disease, or death (whichever occurs first), 1 year.
Secondary outcomes:
Other outcomes:
Locations:
city: Houston
country: United States
facility: MD Anderson Cancer Center
state: Texas
Study officials:
affiliation: M.D. Anderson Cancer Center
name: Jorge Cortes, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02893410: Drug Observance and Side Effects of Cytoreductive Drugs in PV and ET Patients
Official title: Etude de l'Observance thérapeutique et Des Effets Secondaires Des Traitements Chez Les Patients traités Pour Polyglobulie de Vaquez et thrombocytémie Essentielle
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Polycythemia Vera
Essential Thrombocythemia
Lead sponsor: University Hospital, Brest
Sponsor class: OTHER
First posted: 2016-09-08
Enrollment: 286
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with PV or ET who took oral or sub-cutaneous drugs to treat MPN disorders.

Brief summary: Patients treated with oral or sub-cutaneous drugs for polycythemia vera or essential thrombocythemia completed an unique paper questionnaire in order to describe their observance, the side effects and their own appreciation of the taken drug.

Detailed description: During one year, all patients with PV or ET followed in our centre, and who took a drug to treat their MPN, were identified.

The investigators submitted by mail or directly at the consultation a unique questionnaire containing 25 questions concerning patients characteristics, evaluation of observance, identification of side effects and own appreciation of the drug.

After completion of the questionnaire, the patients were identified and followed to collect new data about thrombotic events or phenotypic evolution.

Eligibility criteria: Inclusion Criteria:

* Patients with PV or ET or SMF
* Patients who took oral or sub-cutaneous drugs to treat their MPN.
* Patients who agreed to complete the questionnaire

Exclusion Criteria:

* Patients with low risk PV or ET who do not take treatment
* Patients unable to complete the questionnaire

Primary outcomes:
measure: Rate of adherence to drug prescription
timeFrame: At inclusion
Secondary outcomes:
Other outcomes:
Locations:
city: Brest
country: France
facility: CHRU de Brest
Study officials:
affiliation: CHRU de Brest
name: Jean-Christophe Ianotto, MD
role: STUDY_DIRECTOR
References:
citation: Le Calloch R, Lacut K, Le Gall-Ianotto C, Nowak E, Abiven M, Tempescul A, Dalbies F, Eveillard JR, Ugo V, Giraudier S, Guillerm G, Lippert E, Berthou C, Ianotto JC. Non-adherence to treatment with cytoreductive and/or antithrombotic drugs is frequent and associated with an increased risk of complications in patients with polycythemia vera or essential thrombocythemia (OUEST study). Haematologica. 2018 Apr;103(4):607-613. doi: 10.3324/haematol.2017.180448. Epub 2017 Dec 15.
Clinical trial NCT04392310: Outcomes of Acute Myeloid Leukemia Patients
Official title: Outcomes of Acute Myeloid Leukemia Patients in Assiut University Hospital
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Acute Myeloid Leukemia
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2020-05-18
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Acute myeloid leukemia patients outcomes

Brief summary: 1. To assess overall survival of AML patient.
2. To measure rate of disease free survival.
3. rate of non relapse mortality.
4. rate of complete remission .
5. percentage of refractory disease.
6. percentage of relapsed disease.

Detailed description: Acute myeloid leukemia (AML) is a malignant disorder of the bone marrow which is characterized by malignant clonal expansion and differentiation arrest of myeloid progenitor cells.

The etiology of AML is heterogeneous. In some patients, prior exposure to therapeutic, occupational or environmental DNA-damaging agents is implicated, but most cases of AML remain without a clear etiology.

The incidence of AML had been higher than that of the other three subtypes of leukemia ( \[ALL\], \[CML\], and \[CLL\])\& accounts for the highest percentage (62%) of leukemic deaths.

AML is primarily a disease of older adults. The age-adjusted incidence for those aged 65 years or older is 20.1 per 100,000 persones in comparison to 2.0 per 100,000 person-years for those younger than 65 years old.

Males are 1.2-1.6 times more likely to develop AML during their lifetime as evidenced by population-based studies in the US, UK, Canada, Denmark, Australia and Algeria. AML is one of the most common form of Hematological Malignancy in adults and has the shortest survival (5-year survival = 24%). Curative therapies, including intensive chemotherapy and allogeneic stem cell transplantation, are generally applicable to a minority of patients who are younger and fit, while most older individuals exhibit poor prognosis and survival. Differences in patient outcomes are influenced by disease characteristics, access to care including active therapies and supportive care, and other factors. After many years without therapeutic advances, several new therapies have been approved and are expected to impact patient outcomes, especially for older patients and those with refractory disease.

Eligibility criteria: Inclusion Criteria:

* AML patients, aged more than 18yrs and received chemotherapy (aggressive or palliative).

Exclusion Criteria:

* patients less than 18years old.

Primary outcomes:
measure: Assessment of the overall survival of AML patients.
timeFrame: One year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: De Kouchkovsky I, Abdul-Hay M. 'Acute myeloid leukemia: a comprehensive review and 2016 update'. Blood Cancer J. 2016 Jul 1;6(7):e441. doi: 10.1038/bcj.2016.50.